StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd > Q1 Conference Call Transcript

<< Previous

Bullboard Posts

Next >>

Comment by Jonnyboy85on May 19, 2021 1:39pm

77 Views

Post# 33230876

RE:RE:Q1 Conference Call Transcript

Just in case you missed this as well

Jonnyboy85 wrote:
Jonnyboy85 wrote: https://seekingalpha.com/article/4429384-stagezero-life-sciences-ltd-gnwsf-ceo-james-howard-tripp-on-q1-2021-results-earnings-call

I like this excerpt,

"I'd like to summarize our milestones for the remainder of the year. In the second quarter, we're focused on the following goals. First, we're ramping up our marketing to target patients and families within our US Care Oncology network. Second, we are planning to launch broad-based social media marketing, with the launch of direct-to-consumer campaigns, for AVRT and Aristotle in key markets. And finally, we plan to close on the Care Oncology acquisition.
For the remainder of the year, we are planning a marketing campaign targeting B2B partners, including channel partners, and self-insured, and re-insureds. Second, we're targeting to launch employer pilot programs with innovators and early adopter employer groups. And third, we're planning multi-channel marketing with national B2B and B2C campaigns. The achievement of these milestones will further advance our strategy to capitalize on the strong liquid biopsy and telehealth trends, and to grow our company for the long term. As we move forward, we will continue to execute on our long-term strategy, that includes; generating near term revenue through COVID testing, expanding the use of our Aristotle multi-cancer panel, managing a complete cancer patient journey from liquid biopsy testing, telehealth and adjunctive treatment, and leveraging our technology to broaden into intervention of other chronic diseases."